2015-16 Influenza Activity and Clinical Recommendations

Clinician Outreach and Communication Activity (COCA) Conference Call
February 16, 2016
Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hours.

IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-083-L04-P and enduring 0387-0000-16-083-H04-P. This activity is knowledge based.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.2 hours of continuing education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
Continuing Education Disclaimer

CDC, our planners, presenter, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias. This presentation will not include any discussion of the unlabeled use of a product or products under investigational use.
Objectives

At the conclusion of this session, the participant will be able to:

- Describe the current status of influenza activity in the United States
- Discuss the circulating influenza strains seen this season and the implications for clinicians
- Discuss the use of influenza diagnostic tests and their role in clinical care
- Discuss antiviral treatment and implications for patient evaluation, treatment and testing
Today’s Presenter

Fiona Havers, MD, MHS
Medical Officer
Epidemiology and Prevention Branch, Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Influenza Season Timing

- Timing of influenza activity in the United States can be variable
- Most often peaks between January and March
- During the three most recent influenza seasons, activity began relatively early, and peaked in late December and early January.
- The current season activity began to increase in mid-December, a more typical influenza activity pattern.
SUMMARY OF 2015-16 INFLUENZA ACTIVITY
Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINET, week ending February 6, 2016
Weekly Influenza Activity Estimates Reported by State & Territorial Epidemiologists*

Week ending February 6, 2016 - Week 5

* This map indicates geographic spread & does not measure the severity of influenza activity
Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient ILI Surveillance Network (ILINet), 2015-2016 and Selected Previous Seasons
Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, 2015–2016 Season
Age group distribution of influenza positive specimens* reported by public health laboratories — October 4, 2015 to February 6, 2016

- Age 0-4 years
- Age 5-24 years
- Age 25-64 years
- Age >64 years

Legend:
- A (H1N1)pdm09
- A (H3N2)
- A (subtyping not performed)
- B (lineage not performed)
- B (Victoria lineage)
- B (Yamagata lineage)
Laboratory-Confirmed Influenza Hospitalizations
Preliminary cumulative rates as of Feb 6, 2016
Laboratory-Confirmed Influenza Hospitalizations, Children 0 to 4 years
Preliminary cumulative rates as of Feb 6, 2016
Laboratory-Confirmed Influenza Hospitalizations, Adults ≥65 years
Preliminary cumulative rates as of Feb 6, 2016

Current season
Laboratory-Confirmed Influenza Hospitalizations
Preliminary data as of Feb 6

Selected Underlying Medical Conditions: 2015-16 Season

- Asthma
- Cardiovascular disease
- Chronic lung disease
- Immune suppression
- Metabolic disorder
- Neurologic disorder
- Neuromuscular disorder
- Obesity
- Pregnancy
- Renal disease
- No known condition

Underlying conditions:
89% of adults
47% of children
Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System
Data through the week ending January 23, 2016, as of February 11, 2016
Number of Influenza-Associated Pediatric Deaths by Week of Death: 2012-2013 season to present

- 2012-2013: Number of Deaths Reported = 171
- 2013-2014: Number of Deaths Reported = 111
- 2014-2015: Number of Deaths Reported = 148
- 2015-2016: Number of Deaths Reported = 11

Week of Death

- Deaths Reported Previous Week
- Deaths Reported Current Week
Reports of severe disease

- In recent weeks, CDC has received reports from several states of severe respiratory illnesses among young- to middle-aged adults
  - Patients requiring intubation
  - Fatalities
- Infected with influenza A(H1N1)pdm09 viruses
Some of these patients reportedly tested negative for influenza by rapid influenza diagnostic tests (RIDTs)
- Influenza diagnosis was made later with molecular assays

Most of these patients were reportedly unvaccinated.
Flu Season Begins: Severe Influenza Illness Reported

CDC urges rapid antiviral treatment of very ill and high risk suspect influenza patients without waiting for testing
Reminders to clinicians

- H1N1 virus infection in the past has caused severe illness in some children and young- and middle-aged adults.
- Promptly start antiviral treatment of severely ill and high-risk patients if influenza is suspected or confirmed.
- A negative rapid influenza antigen diagnostic test does not exclude a diagnosis of influenza
  - Treatment should not be delayed even for a few hours to wait for the results of testing
Influenza Vaccinations

- Most of the influenza viruses characterized from October to February are antigenically similar to vaccine viruses strains recommended for inclusion in the 2015-16 Northern Hemisphere vaccines.
- No interim vaccine effectiveness (VE) estimates available yet.
- Clinicians should continue to vaccinate patients this season for as long as influenza viruses are circulating.
- Annual vaccination recommended for all persons ≥6 months
Summary: Influenza season to date

- Activity began to increase in late December 2015
- Continues to increase slowly through early February 2016
- Influenza A(H1N1) viruses are currently the most frequently identified viruses
  - Reports of severe disease in some children and young and middle-aged adults
Testing Guidance

Persons who should be tested during the flu season:

- High risk outpatients with ARI, 5 days from illness onset
- Hospitalized patients with fever and ARI any time from illness onset
- Elderly and infants with sepsis
- Immunocompromised patients with ARI
CDC testing guidance: Will result change clinical care?

Does the patient have clinical signs and symptoms compatible with influenza?¹

- **YES**
  - Will the results of influenza virus testing*:
    - change clinical care of the patient² (especially for hospitalized patients and those with high risk conditions)
    - or
    - influence clinical practice for other patients³
  - Consider influenza virus testing.
    - (See Table 1 below for review of influenza virus testing methods and Table 2 below for review of available RIDTs).
  - Interpret influenza test results.
    - (See Figure 3 below for RIDTs).

- **NO**
  - Influenza virus testing probably not indicated.

- **NO**
  - Influenza virus testing probably not indicated.

*Initiation of antiviral treatment, if clinically indicated, should not be delayed pending results of testing.

http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm#figure1
# Influenza Diagnostic Tests

## Table 1: Influenza Virus Testing Methods

<table>
<thead>
<tr>
<th>Method</th>
<th>Types Detected</th>
<th>Acceptable Specimens</th>
<th>Test Time</th>
<th>CLIA Waived</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral cell culture (conventional)</td>
<td>A and B</td>
<td>NP(^4) swab, throat swab, NP(^2) or bronchial wash, nasal or endotracheal aspirate, sputum</td>
<td>3-10 days</td>
<td>No</td>
</tr>
<tr>
<td>Rapid cell culture (shell vials; cell mixtures)</td>
<td>A and B</td>
<td>As above</td>
<td>1-3 days</td>
<td>No</td>
</tr>
<tr>
<td>Immunofluorescence, Direct (DFA) or Indirect (IFA) Antibody Staining</td>
<td>A and B</td>
<td>NP(^4) swab or wash, bronchial wash, nasal or endotracheal aspirate</td>
<td>1-4 hours</td>
<td>No</td>
</tr>
<tr>
<td>RT-PCR(^2) (singleplex and multiplex; real-time and other RNA-based) and other molecular assays</td>
<td>A and B</td>
<td>NP(^4) swab, throat swab, NP(^2) or bronchial wash, nasal or endotracheal aspirate, sputum</td>
<td>Varied (Generally 1-6 hours)</td>
<td>No</td>
</tr>
<tr>
<td>Rapid Influenza Diagnostic Tests(^6) (antigen)</td>
<td>A and B</td>
<td>NP(^4) swab, (throat swab), nasal wash, nasal aspirate</td>
<td>&lt;30 min.</td>
<td>Yes/No</td>
</tr>
</tbody>
</table>

http://www.cdc.gov/flu/professionals/diagnosis/rapidclin.htm#table
Rapid Influenza Diagnostic Tests ("Rapid Tests")

- Results available ~15-20 min
- Point of care (POC)
-Insensitive (~40-70% c/w PCR)
- When prevalence low, specificity reduced
- False negatives frequent
What do we know about antiviral use and diagnostic testing for influenza?

- Survey of outpatient providers: Use of Rapid Influenza Diagnostic Tests, 2010
- 80-90% reported use of RIDTs to confirm influenza before antivirals prescribed

Williams, et al, J Clin Vir 2014
Testing in high-risk outpatients with acute respiratory illness

- Many come to clinic >2 days after illness onset
- Antiviral drugs are used less commonly prescribed than antibiotics
- RIDT is preferred diagnostic, clinicians treat based on test result
- RIDTs often give false negatives
Diagnostic Tests Performed in Hospital Laboratories, FluSurv-NET (n=240)

- 67% relied ONLY on RIDT to diagnose influenza
- 26% reported the availability of molecular diagnostic assays for detection of influenza
- Testing for other viruses less common


Testing in Hospitalized ARI patients

- In recent seasons, most hospitalized patients with positive influenza test were treated in US
- Testing for influenza not common
- Tests with results available quickly were used more
  - RIDT still used by most hospital laboratories in 2012/13
- Antiviral treatment strongly associated with influenza testing
  - Empiric treatment was uncommon
Reminders to Clinicians (2)

- Influenza should be high on the list of possible diagnoses for ill patients
- A negative rapid influenza antigen diagnostic test (RIDT) does not exclude a diagnosis of influenza
- All hospitalized and all high-risk patients with suspected or confirmed influenza should be treated as soon as possible without waiting for confirmatory testing
Antiviral Use

- Evidence from current and previous influenza seasons suggests that antiviral drugs are underutilized
  - Low awareness of antiviral recommendations
  - Wide range in perception about antiviral effectiveness
  - Many clinicians may require a positive diagnostic test before prescribing; results of rapid influenza diagnostic tests (not molecular) may not be accurate
  - Some clinicians may not prescribe after the 48-hour window that is optimal for treatment
Outpatients with Acute Respiratory Illness Treated with an Influenza Antiviral Medication or Antibiotics During Influenza Season, US Flu VE Network, 2012-13

* Antibiotics limited to amoxicillin, amoxicillin-clavulanate, and azithromycin

Data from Havers, et al. CID 2014;59(6):774-82
Antiviral Medications

- **Oral oseltamivir (Tamiflu®)**
  - Recommended for treatment of all ages, chemoprophylaxis for age ≥3 months

- **Inhaled zanamivir (Relenza®)**
  - Recommended for treatment for age ≥7 years, chemoprophylaxis for age ≥5 years

- **Intravenous peramivir (Rapivab®)**
  - Approved on December 19, 2014, for treatment of acute uncomplicated influenza in persons ≥18 years
  - 600 mg dose infused over 15-30 min
Adverse Events

- Oral oseltamivir: Slightly increased risk of nausea, vomiting over placebo
  - Mild, transient
  - Improved when taken with food

- Inhaled zanamivir: Cases of bronchospasm reported during postmarketing – not recommended for persons with underlying airways disease such as asthma, COPD

- Intravenous peramivir: Slightly increased risk of diarrhea, neutropenia over placebo
CDC Influenza Treatment Guidelines

- **Focus is on prevention of severe outcomes**
  - Treatment of those with severe disease and persons at highest risk of severe influenza complications
  - No RCTs available

- **Include observational studies and meta-analyses of antiviral effectiveness**

- **Antiviral recommendations are common to ACIP, IDSA, AAP**
All patients in the following categories with suspected or confirmed influenza should be treated as soon as possible, without waiting for confirmatory influenza testing:

- Hospitalized patients
- Patients with severe, complicated, or progressive illness
- Patients at high risk for complications from influenza (either outpatient or hospitalized)
Antiviral treatment may be prescribed on the basis of clinical judgment for any previously healthy (non-high risk) outpatient with suspected or confirmed influenza.
Persons at High Risk for Influenza Complications

- Children <2 years
- Adults ≥65 years
- Pregnant and postpartum women (within 2 weeks after delivery)
- American Indians and Alaska Natives
- Persons who are morbidly obese (BMI ≥40)
- Residents of long-term care facilities
Persons at High Risk for Influenza Complications (continued)

- Persons with immunosuppression
- Persons <19 years who are receiving long-term aspirin therapy
- Persons with underlying medical conditions: chronic pulmonary, cardiovascular (except hypertension alone), renal, hepatic, hematologic, and metabolic disorders (incl. diabetes), or neurologic and neurodevelopment conditions
Timing of Treatment

- When indicated, antiviral treatment should be started as soon as possible after illness onset.
- Ideally, treatment should be initiated within 48 hours of symptom onset.
- Treatment should not be delayed even for a few hours to wait for the results of testing.
  - A negative rapid influenza antigen diagnostic test does not exclude a diagnosis of influenza.
High-Risk Outpatients and Early Treatment

- During influenza season, providers should advise high-risk patients to call promptly if they have symptoms of influenza
- Phone triage lines may be useful to enable high risk patients to discuss symptoms over the phone
- To facilitate early initiation of treatment, when feasible, an antiviral prescription can be provided without testing and before an office visit
Antiviral Treatment Initiated after 48 Hours Can Still be Beneficial in Some Patients

- Observational studies of hospitalized patients suggest that treatment might still be beneficial when initiated 4 or 5 days after symptom onset.
- Observational data in pregnant women has shown antiviral treatment to provide benefit when started 3-4 days after onset.
- A randomized placebo controlled study suggested clinical benefit when oseltamivir was initiated 72 hours after illness onset among febrile children with uncomplicated influenza.

Outpatient Treatment

- Any neuraminidase inhibitor may be used for treatment of outpatients
  - 5-day course of oseltamivir or inhaled zanamivir
  - 1-day of IV peramivir

- Oral oseltamivir is preferentially recommended for pregnant women
Treatment for Hospitalized Patients

- Treatment with oral or enterically administered oseltamivir is recommended
  - Limited data suggest that oseltamivir administered by oro/naso gastric tube is well absorbed in critically ill influenza patients, including those in the intensive care unit, on continuous renal replacement therapy, and/or on extracorporeal membrane oxygenation

- Inhaled zanamivir is not recommended because of lack of data for use in patients with severe influenza disease

- Insufficient data regarding efficacy of intravenous peramivir for hospitalized patients

- For patients who remain severely ill after 5 days of treatment, longer treatment courses may be considered
Treatment for Hospitalized Patients: Concern Regarding Oseltamivir Absorption

- For patients who cannot tolerate or absorb oral oseltamivir because of suspected or known gastric stasis, malabsorption, or gastrointestinal bleeding, the use of IV peramivir or investigational IV zanamivir should be considered
  - If peramivir used in severely ill patients, single dose should not be given
  - For severely ill patients, adult dose of 600 mg IV once daily for 5 days is recommended (dose for children >6 years: 10 mg/kg once daily [up to 600 mg] for 5 days); minimum of 5 days duration

De Jong, et al. CID 2014; 59:172-85
Treatment for Hospitalized Patients: Concern Regarding Oseltamivir Resistance

- Some influenza viruses may become resistant to oseltamivir and peramivir during antiviral treatment with one of these agents and remain susceptible to zanamivir
  - Investigational use of intravenous zanamivir should be considered for treatment of severely ill patients with oseltamivir-resistant virus infection
Additional Information: Antibiotics and Bacterial Infections

- Antibiotics are not effective against influenza
- Several reports suggest inappropriate use of antibiotics for patients with influenza
- Bacterial infections can occur as a complication of influenza, so should be considered and appropriately treated if suspected
Use of antiviral chemoprophylaxis to control outbreaks among high-risk persons in institutional settings is recommended

- For all residents (regardless of vaccination status)
- For unvaccinated healthcare personnel
- For a minimum of 2 weeks, continuing at least 7 days after last known case identified
Summary of Antiviral Recommendations

- Early empiric antiviral treatment is recommended for suspected or confirmed influenza among the following:
  - Hospitalized patients
  - Patients with severe or progressive illness
  - Patients at high risk for complications

- Decisions about antiviral treatment should not wait for laboratory confirmation of influenza

- Clinical benefit is greatest when antiviral treatment is initiated early, but treatment initiated later than 48 hours after onset can still be beneficial for some patients
Influenza activity is increasing
Vaccination still possible
H1N1 viruses now most frequently detected, but H3N2 and influenza B viruses also seen
Can expect to see some severe disease in children and young and middle-aged adults
Decisions regarding treatment should not be made on the basis of a negative RIDT
For Additional Information

- **Summary of Influenza Antiviral Treatment Recs for Clinicians:** [http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm](http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm)


- **Interim Guidance for Influenza Outbreak Management in Long-Term Care Facilities:** [http://www.cdc.gov/flu/professionals/infectioncontrol/ltc-facility-guidance.htm](http://www.cdc.gov/flu/professionals/infectioncontrol/ltc-facility-guidance.htm)

- **Prevention Strategies for Seasonal Influenza in Healthcare Settings** [http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm](http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm)

- **FDA Influenza (Flu) Antiviral Drugs and Related Information (including package inserts):** [http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm100228.htm](http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm100228.htm)

- **American Academy of Pediatrics (AAP) Information on Influenza in Children:** [www.aap.org/disasters/flu](http://www.aap.org/disasters/flu)
Acknowledgements

- Influenza Division CDC
  - Angela Campbell
  - Alicia Fry
  - Communications team
To Ask a Question

- **Using the Webinar System**
  - “Click” the Q&A tab at the top left of the webinar tool bar
  - “Click” in the white space
  - “Type” your question
  - “Click” ask

- **On the Phone**
  - Press Star (*) 1 to enter the queue
  - State your name
  - Listen for the operator to call your name
  - State your organization and then ask your question
Thank you for joining!
Please email us questions at coca@cdc.gov

Centers for Disease Control and Prevention
Atlanta, Georgia

http://emergency.cdc.gov/coca
Continuing Education for COCA Calls

Continuing Education guidelines require that the attendance of all who participate in COCA Conference Calls be properly documented. All Continuing Education credits/contact hours (CME, CNE, CEU, CECH, ACPE and AAVSB/RACE) for COCA Conference Calls/Webinars are issued online through the CDC Training & Continuing Education Online system (http://www.cdc.gov/TCEOnline/).

Those who participate in the COCA Conference Calls and who wish to receive CE credit/contact hours and will complete the online evaluation by February 29, 2016 will use the course code WC2286. Those who wish to receive CE credits/contact hours and will complete the online evaluation between March 1, 2016 and March 1, 2018 will use course code WD2286. CE certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the CDC Training & Continuing Education Online System will be maintained for each user.
Join Us on Facebook

CDC Facebook page for clinicians! “Like” our page today to learn about upcoming COCA Calls, CDC guidance and recommendations, and other health alerts

CDC Clinician Outreach and Communication Activity
https://www.facebook.com/CDCClinicianOutreachAndCommunicationActivity